# A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

> **NCT02350673** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 70 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cergutuzumab Amunaleukin

## Key facts

- **NCT ID:** NCT02350673
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-29
- **Primary completion:** 2019-12-16
- **Final completion:** 2019-12-16
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02350673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02350673, "A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02350673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*